Beta-alanineBETA_TENNISNCT05427409
Ingestion of Beta-alanine Effects in Well-trained Tennis Players
A study testing Beta-alanine supplementation in people with Beta-alanine and Placebo, run by Universidad Francisco de Vitoria at 1 site in Spain.
Trial summary
Beta-alanine is considered as ergogenic aids with good to strong evidence for improving sports performance in specific sports context scenarios. However, most of the studies has been realized in endurance, with limited evidence in intermittent sports, especially in racket sports. Read more about this study
- Who is it for?
- Ages 18 to 35 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Beta-alanine, Placebo
- What is being tested?
- Beta-alanine supplementation
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 14 participants
- Where
- 1 siteSpain
- Study dates
- 4 Nov 2020to 1 Jun 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Well-trained tennis players, between 18-35 years old (50-200 between tennis ranking)
Who cannot join
- Suffering from any chronic pathology or an injury in the month prior to the investigation.
- Intolerance to beta-alanine ingestion
- Amateur tennis players.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Ingestion of Beta-alanine Improves Neuromuscular Performance in Well-trained Tennis. A Randomized Controlled Trial.
Beta-alanine is considered as ergogenic aids with good to strong evidence for improving sports performance in specific sports context scenarios. However, most of the studies has been realized in endurance, with limited evidence in intermittent sports, especially in racket sports. Thus, the aim of this study was to explore the effects of 4-weeks ingestion of beta-alanine on neuromuscular performance in well-trained tennis players.
Read the detailed description
Fourteen tennis players (23.3 ±3.7 years) between 50-250 national tennis ranking participated in this study. Participants were randomly divided into two groups that realized a neuromuscular battery after beta-alanine (4.8 gr/daily during 4-weeks) or placebo (i.e., fructose) (4.8 grams/daily during 4-weeks). Before and after the supplementation period tennis performed a neuromuscular test battery in a tennis court consisted in different test such as; serve velocity, countermovement jump, isometric handgrip strength, 10-m sprint, modified 5-0-5 agility test and repeated sprint ability. After 48 h of the realization of neuromuscular test battery, tennis players performed VO2max consumption test (i.e., treadmill).
- Conditions
- Beta-alanine, Placebo
- Being tested
- Beta-alanine supplementation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Beta-alanine supplementationDietary supplement
Also called Placebo supplementation
In a randomized order, two groups (n=7) was randomly assigned to beta-alanine and placebo during a 4-weeks period
| Study group | Role | What they receive |
|---|---|---|
| Beta-alanine supplementation | Active comparator | Beta-alanine (4.8 grams) pills (Crown Nutrition, Haro, Spain) in four doses each day during a 4-week supplementation period. Receives: Dietary Supplement: Beta-alanine supplementation |
| Placebo supplementation | Placebo comparator | Placebo (4.8 grams) pills (Crown Nutrition, Haro, Spain) contain fructose (300mg) and excipients (1200 mg) such as cellulose, calcium phosphate, silicon dioxide and magnesium stearate in four doses each day during a 4-week supplementation period. Receives: Dietary Supplement: Beta-alanine supplementation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Repeated sprint ability test.
Infrared photocells system (Microgate, Italy)
Measured: 4-weeks
VO2 max treadmill test
Using VO2 max analyzer (Ergostik, Geratherm Respiratory, Ergostik, Geratherm, Germany)
Measured: 4-weeks
Secondary outcomes (5)
Serve velocity
Stroke velocity radar gun (Radar Pocket, South Korea)
Measured: 4-weeks
Contermovement Jump
Contact Jump (Chronojump, Spain)
Measured: 4-weeks
10m sprint
Infrared photocells system (Microgate, Italy)
Measured: 4-weeks
Isometric handgrip strength
Hand held dynamometer (Takei, Japan)
Measured: 4-weeks
Modified agility test 5-0-5
Infrared photocells system (Microgate, Italy)
Measured: 4-weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2022
- Study start4 Nov 2020
- Primary completion1 Jun 2021
- Study completion1 Jun 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Beta-alanineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 14 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidad Francisco de Vitoria
- Sponsor type
- University, hospital or other
- Collaborators
- University of Seville, University of Greenwich
- Responsible party
- Sponsor
- Investigators
- Iñaki Quintana García-Milla, PhD, Principal investigator, Universidad Francisco de Vitoria
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05427409
- Sponsor's protocol ID
- UFran_Vitoria
- Acronym
- BETA_TENNIS
- Status last verified
- Jun 2022
- First submitted
- 16 Jun 2022
- Last updated
- 22 Jun 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ingestion of Beta-alanine Improves Neuromuscular Performance in Well-trained Tennis. A Randomized Controlled Trial.
- ClinicalTrials.gov ID
- NCT05427409
- Acronym / sponsor ID
- BETA_TENNIS / UFran_Vitoria
- Conditions
- Beta-alanine, Placebo
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 14 participants (actual)
- Lead sponsor
- Universidad Francisco de VitoriaUniversity, hospital or other
- Collaborators
- University of Seville, University of Greenwich
- Study start
- 4 Nov 2020 (actual)
- Primary completion
- 1 Jun 2021 (actual)
- Study completion
- 1 Jun 2021 (actual)
- First posted
- 22 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Beta-alanine is considered as ergogenic aids with good to strong evidence for improving sports performance in specific sports context scenarios. However, most of the studies has been realized in endurance, with limited evidence in intermittent sports, especially in racket sports. Thus, the aim of this study was to explore the effects of 4-weeks ingestion of beta-alanine on neuromuscular performance in well-trained tennis players.
Detailed description
Fourteen tennis players (23.3 ±3.7 years) between 50-250 national tennis ranking participated in this study. Participants were randomly divided into two groups that realized a neuromuscular battery after beta-alanine (4.8 gr/daily during 4-weeks) or placebo (i.e., fructose) (4.8 grams/daily during 4-weeks). Before and after the supplementation period tennis performed a neuromuscular test battery in a tennis court consisted in different test such as; serve velocity, countermovement jump, isometric handgrip strength, 10-m sprint, modified 5-0-5 agility test and repeated sprint ability. After 48 h of the realization of neuromuscular test battery, tennis players performed VO2max consumption test (i.e., treadmill).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Beta-alanine supplementation | Active comparator | Dietary Supplement: Beta-alanine supplementationBeta-alanine (4.8 grams) pills (Crown Nutrition, Haro, Spain) in four doses each day during a 4-week supplementation period. |
| Placebo supplementation | Placebo comparator | Dietary Supplement: Beta-alanine supplementationPlacebo (4.8 grams) pills (Crown Nutrition, Haro, Spain) contain fructose (300mg) and excipients (1200 mg) such as cellulose, calcium phosphate, silicon dioxide and magnesium stearate in four doses each day during a 4-week supplementation period. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Well-trained tennis players, between 18-35 years old (50-200 between tennis ranking)
Key exclusion criteria (3 listed)
- Suffering from any chronic pathology or an injury in the month prior to the investigation.
- Intolerance to beta-alanine ingestion
- Amateur tennis players.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Beta-alanine supplementationAlso: Placebo supplementationIn a randomized order, two groups (n=7) was randomly assigned to beta-alanine and placebo during a 4-weeks period | Dietary supplement | Beta-alanine supplementation, Placebo supplementation |
Primary outcome
Repeated sprint ability test.
Time frame: 4-weeks
Infrared photocells system (Microgate, Italy)
VO2 max treadmill test
Time frame: 4-weeks
Using VO2 max analyzer (Ergostik, Geratherm Respiratory, Ergostik, Geratherm, Germany)
5 secondary outcomes
Serve velocity
Time frame: 4-weeks
Contermovement Jump
Time frame: 4-weeks
10m sprint
Time frame: 4-weeks
Isometric handgrip strength
Time frame: 4-weeks
Modified agility test 5-0-5
Time frame: 4-weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2022.
- Individual participant dataSharing planned: No
Related trials for Beta-alanine
Enrolling by invitation
Beta-Alanine Effects on Neuromuscular and Cardiovascular Performance in Female Rugby Players
Beta Alanine Supplementation, Placebo - Control
Active, not recruiting
An Initial Investigation Into the Effects of β-Alanine on Performance and Physiological Responses During Simulated Wrestling Matches
Healthy, Athletes
RecruitingPhase 3
Effects of β-alanine and Sodium Bicarbonate Supplementation on Physical Capacity and Biochemical Markers Concentrations
Supplementation, Sports
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Iñaki Quintana García-Milla, PhD principal investigator
Universidad Francisco de Vitoria
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Beta-alanine supplementation in people with Beta-alanine and Placebo, run by Universidad Francisco de Vitoria at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Repeated sprint ability test. (time frame: 4-weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2022.